Nanjing King-friend Stock Hits Day Low Amid Price Pressure at CNY 7.43

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.61% on June 15, 2026. The stock reached an intraday low of CNY 7.43, reflecting ongoing challenges in its market performance. Over the past week, the stock has decreased by 5.32%, and its one-month performance shows a significant drop of 14.14%. In the context of longer-term performance, Nanjing King-friend has faced substantial setbacks, with a year-to-date decline of 17.28% and a staggering 33.95% decrease over the past year. The company has consistently underperformed against the China Shanghai Composite, which has shown a positive return of 21.31% over the same period. Financial metrics indicate a mixed picture, with a return on equity of 10.58% and a price-to-book ratio of 2.58. Despite a high dividend yield of 1.24%, the company has reported negative net profit growth and a low interest coverage ratio, raising concerns about its financial stability. As a large-cap player in the pharmaceuticals and biotechnology sector, Nanjing King-friend continues to navigate a challenging landscape.